AR096425A1 - Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona - Google Patents
Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-onaInfo
- Publication number
- AR096425A1 AR096425A1 ARP140102073A ARP140102073A AR096425A1 AR 096425 A1 AR096425 A1 AR 096425A1 AR P140102073 A ARP140102073 A AR P140102073A AR P140102073 A ARP140102073 A AR P140102073A AR 096425 A1 AR096425 A1 AR 096425A1
- Authority
- AR
- Argentina
- Prior art keywords
- dihidro
- ona
- cycloalkyl
- alkyl
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Compuestos de fórmula (1) en la que R¹, R², R³ y R⁴ se seleccionan independientemente entre H, alquilo y cicloalquilo; R⁵, R⁷ y R⁹ se seleccionan independientemente entre H o alquilo; R⁸ y R¹¹ en conjunto forman -CH₂-CH₂-; R¹⁰ es H o R¹⁰ y R¹¹ en conjunto forman -(CH₂)ʷ-; o R⁶ y R⁹ en conjunto forman -CH₂-, R⁸ es H y R¹⁰ y R¹¹ en conjunto forman -CH₂-; A es -C(O)- o -S(O)₂-; B es -C- o -N-; R¹² es cicloalquilo o heteroarilo sustituido, en el que heteroarilo sustituido está sustituido con uno a tres sustituyentes seleccionados independientemente entre H, alquilo, cicloalquilo, hidroxi, alcoxi, ciano y halógeno; R¹³ es halógeno, ciano, alcoxi o haloalcoxi; R¹⁴ es H, alquilo o cicloalquilo; R¹⁵ es H, alquilo, cicloalquilo o halógeno; m, n y p se seleccionan independientemente entre cero y 1; w es 1, 2 ó 3; y sales farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013076285 | 2013-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR096425A1 true AR096425A1 (es) | 2015-12-30 |
Family
ID=50819739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140102073A AR096425A1 (es) | 2013-05-27 | 2014-05-26 | Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9695152B2 (es) |
| EP (1) | EP3004076B1 (es) |
| JP (2) | JP6416230B2 (es) |
| AR (1) | AR096425A1 (es) |
| BR (1) | BR112015029691B1 (es) |
| CA (1) | CA2902848C (es) |
| DK (1) | DK3004076T3 (es) |
| ES (1) | ES2763424T3 (es) |
| HK (1) | HK1213556A1 (es) |
| HR (1) | HRP20192242T1 (es) |
| HU (1) | HUE046739T2 (es) |
| LT (1) | LT3004076T (es) |
| MX (1) | MX368759B (es) |
| PL (1) | PL3004076T3 (es) |
| PT (1) | PT3004076T (es) |
| RS (1) | RS59663B1 (es) |
| RU (1) | RU2693698C2 (es) |
| SI (1) | SI3004076T1 (es) |
| TW (1) | TWI704143B (es) |
| WO (1) | WO2014191340A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2695524C2 (ru) * | 2013-05-27 | 2019-07-23 | Ф. Хоффманн-Ля Рош Аг | Производные 3,4-дигидро-2н-изохинолин-1-она и 2,3-дигидроизоиндол-1-oha, полезные в качестве ингибитора альдостеронсинтазы |
| WO2016055394A1 (en) * | 2014-10-08 | 2016-04-14 | F. Hoffmann-La Roche Ag | Spirodiamine derivatives as aldosterone synthase inhibitors |
| US11325896B2 (en) | 2017-12-20 | 2022-05-10 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6482951B2 (en) * | 2000-12-13 | 2002-11-19 | Hoffmann-La Roche Inc. | Isoindolin-1-one glucokinase activators |
| DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| US8946260B2 (en) * | 2010-09-16 | 2015-02-03 | Novartis Ag | 17α-hydroxylase/C17,20-lyase inhibitors |
| CN103814021B (zh) * | 2011-09-15 | 2016-12-21 | 霍夫曼-拉罗奇有限公司 | 二氢喹啉‑2‑酮衍生物 |
| US9353081B2 (en) * | 2011-09-23 | 2016-05-31 | Hoffmann-La Roche Inc. | Bicyclic dihydroquinoline-2-one derivatives |
-
2014
- 2014-05-26 DK DK14726363.6T patent/DK3004076T3/da active
- 2014-05-26 EP EP14726363.6A patent/EP3004076B1/en active Active
- 2014-05-26 RU RU2015149956A patent/RU2693698C2/ru active
- 2014-05-26 MX MX2015015058A patent/MX368759B/es active IP Right Grant
- 2014-05-26 AR ARP140102073A patent/AR096425A1/es active IP Right Grant
- 2014-05-26 RS RS20191616A patent/RS59663B1/sr unknown
- 2014-05-26 SI SI201431431T patent/SI3004076T1/sl unknown
- 2014-05-26 PL PL14726363T patent/PL3004076T3/pl unknown
- 2014-05-26 BR BR112015029691-2A patent/BR112015029691B1/pt active IP Right Grant
- 2014-05-26 WO PCT/EP2014/060794 patent/WO2014191340A1/en active Application Filing
- 2014-05-26 ES ES14726363T patent/ES2763424T3/es active Active
- 2014-05-26 PT PT147263636T patent/PT3004076T/pt unknown
- 2014-05-26 JP JP2016515760A patent/JP6416230B2/ja active Active
- 2014-05-26 CA CA2902848A patent/CA2902848C/en active Active
- 2014-05-26 HU HUE14726363A patent/HUE046739T2/hu unknown
- 2014-05-26 LT LTEP14726363.6T patent/LT3004076T/lt unknown
- 2014-05-26 TW TW103118319A patent/TWI704143B/zh active
-
2015
- 2015-11-20 US US14/947,768 patent/US9695152B2/en active Active
-
2016
- 2016-02-11 HK HK16101487.0A patent/HK1213556A1/zh unknown
-
2018
- 2018-10-03 JP JP2018188236A patent/JP2019014738A/ja active Pending
-
2019
- 2019-12-12 HR HRP20192242TT patent/HRP20192242T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016520106A (ja) | 2016-07-11 |
| HRP20192242T1 (hr) | 2020-03-06 |
| CA2902848C (en) | 2021-09-21 |
| DK3004076T3 (da) | 2020-01-02 |
| SI3004076T1 (sl) | 2020-02-28 |
| MX368759B (es) | 2019-10-15 |
| US20160075688A1 (en) | 2016-03-17 |
| WO2014191340A1 (en) | 2014-12-04 |
| RU2015149956A (ru) | 2017-07-04 |
| EP3004076B1 (en) | 2019-10-23 |
| JP2019014738A (ja) | 2019-01-31 |
| HK1213556A1 (zh) | 2016-07-08 |
| TW201534596A (zh) | 2015-09-16 |
| EP3004076A1 (en) | 2016-04-13 |
| BR112015029691A2 (pt) | 2017-07-25 |
| LT3004076T (lt) | 2020-01-10 |
| PT3004076T (pt) | 2019-12-18 |
| TWI704143B (zh) | 2020-09-11 |
| BR112015029691B1 (pt) | 2023-03-28 |
| MX2015015058A (es) | 2016-02-11 |
| PL3004076T3 (pl) | 2020-04-30 |
| RS59663B1 (sr) | 2020-01-31 |
| JP6416230B2 (ja) | 2018-10-31 |
| HUE046739T2 (hu) | 2020-03-30 |
| ES2763424T3 (es) | 2020-05-28 |
| RU2015149956A3 (es) | 2018-03-19 |
| RU2693698C2 (ru) | 2019-07-04 |
| CA2902848A1 (en) | 2014-12-04 |
| US9695152B2 (en) | 2017-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR123048A2 (es) | Moduladores de p2x7 | |
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| AR103182A1 (es) | Inmunomoduladores | |
| AR099363A1 (es) | Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil y pirrolo[2,3-d]piridinil acrilamidas | |
| AR093036A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| AR092347A1 (es) | Derivados de azaindol | |
| AR092742A1 (es) | Piridinonas antifibroticas | |
| AR104208A1 (es) | Compuestos bicíclicos como inhibidores de autotaxina (atx) | |
| AR096423A1 (es) | Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona | |
| AR097571A1 (es) | Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR100975A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR099824A1 (es) | Compuestos bicíclicos | |
| AR100886A1 (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| AR090488A1 (es) | Derivados de n-ciclobutilbenzamida, un proceso para su obtencion, intermediarios para su sintesis, composiciones pesticidas y farmaceuticas que los comprenden y metodos para controlar daños debidos a una plaga y/u hongos | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR104461A1 (es) | Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil, pirrolo[2,3-b]piridinil acrilamidas y epóxidos de estas | |
| AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR098517A1 (es) | Compuestos derivados de octahidro-ciclobuta[1,2-c;3,4-c]dipirrol-2-ilo | |
| AR092223A1 (es) | Derivados biciclicos de piridina | |
| AR095708A1 (es) | Indazoles sustituidos con diaminoheteroarilo | |
| AR100940A1 (es) | Derivados de 1,2,4-triazoles plaguicidas, y sus intermediarios, composiciones y sus procesos relacionados | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |